Karen Vousden

Q: What Schools Are Affiliated With Karen Vousden

Karen Vousden is affiliated with the following schools: Institute of Cancer Research, St Mary's Hospital Medical School, Queen Mary University of London

Karen Vousden's AcademicInfluence.com Rankings

Karen Vousden

Law

#1281

World Rank

#1628

Historical Rank

Common Law

#22

World Rank

#24

Historical Rank

law Degrees

Download Badge

Why Is Karen Vousden Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Karen Heather Vousden, CBE, FRS, FRSE, FMedSci is a British medical researcher. She is known for her work on the tumour suppressor protein, p53, and in particular her discovery of the important regulatory role of Mdm2, an attractive target for anti-cancer agents. From 2003 to 2016, she was the director of the Cancer Research UK Beatson Institute in Glasgow, UK, moving back to London in 2016 to take up the role of Chief Scientist at CRUK and Group Leader at the Francis Crick Institute.

(See a Problem?)

Karen Vousden's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Regulation of p53 stability by Mdm2 (1997) (3398)
Live or let die: the cell's response to p53 (2002) (3389)
Proliferation, cell cycle and apoptosis in cancer (2001) (3223)
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018) (3106)
Blinded by the Light: The Growing Complexity of p53 (2009) (2841)
PUMA, a novel proapoptotic gene, is induced by p53. (2001) (2311)
p53 in health and disease (2007) (2123)
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes (2009) (2078)
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis (2006) (1815)
p53 mutations in cancer (2013) (1448)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities (2014) (1236)
The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 (1998) (1227)
Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* (2000) (1098)
p14ARF links the tumour suppressors RB and p53 (1998) (1001)
p53 and metabolism (2009) (929)
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. (1989) (906)
p53 in survival, death and metabolic health: a lifeguard with a licence to kill (2015) (823)
Mutant p53 Drives Invasion by Promoting Integrin Recycling (2009) (761)
Serine starvation induces stress and p53 dependent metabolic remodeling in cancer cells (2012) (736)
Role of NF-κB in p53-mediated programmed cell death (2000) (723)
Regulation and function of the p53 tumor suppressor protein. (2001) (715)
Role for the p53 homologue p73 in E2F-1-induced apoptosis (2000) (674)
Regulation of HDM2 activity by the ribosomal protein L11. (2003) (666)
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. (1995) (590)
p73: Friend or foe in tumorigenesis (2002) (584)
Serine and one-carbon metabolism in cancer (2016) (560)
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour (2000) (544)
Serine is a natural ligand and allosteric activator of pyruvate kinase M2 (2012) (515)
Coping with stress: multiple ways to activate p53 (2007) (510)
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation (1991) (508)
A roadmap for interpreting (13)C metabolite labeling patterns from cells. (2015) (468)
Regulation of p53 Function and Stability by Phosphorylation (1999) (467)
p53 and its mutants in tumor cell migration and invasion (2011) (442)
Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. (2014) (430)
Regulation of p53 stability (1999) (423)
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. (2007) (403)
Stress Signals Utilize Multiple Pathways To Stabilize p53 (2000) (396)
Metabolic Regulation by p53 Family Members (2013) (395)
p73 Induces Apoptosis via PUMA Transactivation and Bax Mitochondrial Translocation* (2004) (384)
Metabolic regulation by p53 (2011) (373)
p53 in signaling checkpoint arrest or apoptosis. (1996) (364)
Modulating the therapeutic response of tumours to dietary serine and glycine starvation (2017) (362)
PML regulates p53 stability by sequestering Mdm2 to the nucleolus (2004) (359)
Mechanisms of p53-mediated apoptosis (1999) (344)
Activation of the p53 tumor suppressor protein. (2002) (343)
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. (2005) (341)
Modulation of intracellular ROS levels by TIGAR controls autophagy (2009) (337)
The ubiquitin–protein ligase Itch regulates p73 stability (2005) (326)
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018) (323)
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. (1990) (319)
p53: new roles in metabolism. (2007) (317)
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours (1992) (313)
Activation and activities of the p53 tumour suppressor protein (2001) (309)
Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability (1997) (309)
Induction of DNA synthesis and apoptosis are separable functions of E2F-1. (1997) (305)
Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells (2016) (291)
P53 and Prognosis New Insights and Further Complexity (2005) (289)
Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function (1996) (285)
p53 point mutation in HPV negative human cervical carcinoma cell lines. (1991) (281)
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer (2012) (275)
p53 is frequently mutated in Burkitt's lymphoma cell lines. (1991) (273)
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53‐mediated repression of transcription. (1992) (271)
E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. (1999) (260)
Transcriptional activation by p53 correlates with suppression of growth but not transformation (1994) (259)
C-Terminal Ubiquitination of p53 Contributes to Nuclear Export (2001) (255)
A ribonucleotide reductase gene is a transcriptional target of p53 and p73 (2000) (253)
Role of NF-kappaB in p53-mediated programmed cell death. (2000) (247)
Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. (1994) (241)
INK4a‐deficient human diploid fibroblasts are resistant to RAS‐induced senescence (2002) (237)
A point mutational analysis of human papillomavirus type 16 E7 protein (1989) (233)
C-terminal modifications regulate MDM2 dissociation and nuclear export of p53 (2007) (230)
Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation (1993) (222)
PUMA and Bax-induced Autophagy Contributes to Apoptosis (2009) (221)
Control of glycolysis through regulation of PFK1: old friends and recent additions. (2011) (220)
Ubiquitination and Degradation of Mutant p53 (2007) (215)
Regulation of Mdm2-Directed Degradation by the C Terminus of p53 (1998) (211)
p53, ROS and senescence in the control of aging (2010) (209)
Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. (1994) (207)
Mdm2 binds p73α without targeting degradation (1999) (206)
Outcomes of p53 activation - spoilt for choice (2006) (206)
Phosphorylation of HDM2 by Akt (2002) (205)
Identification of a cryptic nucleolar-localization signal in MDM2 (2000) (204)
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers (2020) (202)
Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression (1998) (196)
Complicating the complexity of p53. (2005) (194)
Characterization of Structural p53 Mutants Which Show Selective Defects in Apoptosis but Not Cell Cycle Arrest (1998) (190)
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion (2012) (188)
p53 regulation of metabolic pathways. (2010) (183)
Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death (2012) (183)
An essential function of the extreme C‐terminus of MDM2 can be provided by MDMX (2007) (181)
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene (1986) (181)
E2F-1 induced apoptosis (2001) (159)
TIGAR Is Required for Efficient Intestinal Regeneration and Tumorigenesis (2013) (157)
Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl (2012) (151)
The role of ROS in tumour development and progression (2022) (147)
Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. (1992) (147)
Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo(a)pyrene diol-epoxide (1984) (144)
The role of ubiquitin modification in the regulation of p53. (2014) (144)
Characterisation of human cyclin G1 and G2: DNA damage inducible genes. (1996) (140)
Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway (2008) (137)
A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3 (2018) (136)
p53, cancer and the immune response (2020) (136)
Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer (1996) (133)
Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes (1998) (131)
Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes (1993) (129)
Keeping an old friend under control: regulation of p53 stability. (1998) (129)
The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. (1988) (129)
Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. (1990) (128)
Mutations activating human c-Ha-ras1 protooncogene (HRAS1) induced by chemical carcinogens and depurination. (1986) (125)
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer (2020) (119)
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. (2010) (118)
Control of metabolism by p53 – Cancer and beyond☆ (2018) (118)
Regulation of the cell cycle by viral oncoproteins. (1995) (117)
Analysis of the degradation function of Mdm2. (1999) (117)
Savior and slayer: the two faces of p53 (2005) (115)
Diacylglycerol kinase α controls RCP-dependent integrin trafficking to promote invasive migration (2012) (115)
Critical Role for a Central Part of Mdm2 in the Ubiquitylation of p53 (2003) (114)
Serine one-carbon catabolism with formate overflow (2016) (110)
Lucifer's labyrinth--ten years of path finding in cell death. (2007) (105)
Interaction of p53 with the CCT Complex Promotes Protein Folding and Wild-Type p53 Activity (2013) (103)
Cell Clustering Promotes a Metabolic Switch that Supports Metastatic Colonization (2019) (103)
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. (2016) (102)
Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections (2020) (102)
Regulation of p53 stability and function by the deubiquitinating enzyme USP42 (2011) (101)
p53 tumour suppressor (1998) (100)
Contribution of two independent MDM2-binding domains in p14ARF to p53 stabilization (2000) (100)
Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization. (1999) (98)
Regulation of Cellular Metabolism and Hypoxia by p53. (2016) (98)
Three different activated ras genes in mouse tumours; evidence for oncogene activation during progression of a mouse lymphoma. (1984) (97)
p53 and PUMA: A Deadly Duo (2005) (96)
Mdm2 binds p73 alpha without targeting degradation. (1999) (95)
Enhanced spontaneous metastasis of mouse carcinoma cells transfected with an activated c‐Ha‐ras‐1 gene (1986) (91)
Oncogenic Kras induces Nix-mediated mitophagy to promote pancreatic cancer. (2019) (90)
Functional interplay between MDM2, p63/p73 and mutant p53 (2014) (89)
The ins and outs of p53 (2000) (89)
Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. (1994) (88)
Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. (1991) (88)
E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. (1996) (87)
Cancer research: past, present and future (2011) (86)
Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation. (2015) (84)
Absence of HPV 16 and 18 DNA in breast cancer. (1992) (82)
A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. (2007) (82)
The role of p53 in glucose metabolism. (2010) (81)
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses (2020) (79)
TIGAR, TIGAR, burning bright (2014) (79)
Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo (2014) (78)
Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels (2018) (77)
Induction of p57KIP2 expression by p73β (2002) (77)
Expression of RB and p53 proteins in HPV‐positive and HPV‐negative cervical carcinoma cell lines (1991) (77)
RELATION BETWEEN INFECTION WITH A SUBTYPE OF HPV16 AND CERVICAL NEOPLASIA (1989) (76)
Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. (1994) (75)
p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival (2011) (72)
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy (2021) (72)
The ERBB network facilitates KRAS-driven lung tumorigenesis (2016) (72)
Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. (1994) (71)
Mutant p53 Regulates Dicer through p63-dependent and -independent Mechanisms to Promote an Invasive Phenotype* (2013) (70)
Modifications of p53: competing for the lysines. (2009) (70)
Opposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine (2016) (70)
Metabolic Regulation by p 53 Family Members (2013) (69)
Human papillomavirus detection by hybrid capture and its possible clinical use. (1994) (69)
Regulation of the p53 pathway by ubiquitin and related proteins. (2010) (69)
Dietary Approaches to Cancer Therapy. (2020) (68)
Mutant p53 interactome identifies nardilysin as a p53R273H‐specific binding partner that promotes invasion (2012) (63)
Interactions between papillomavirus proteins and tumor suppressor gene products. (1994) (62)
Modulation of transcriptional regulatory properties of p53 by HPV E6. (1994) (62)
Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein, TBP. (1997) (61)
Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. (1993) (61)
p73 supports cellular growth through c-Jun-dependent AP-1 transactivation (2007) (61)
HDM2 phosphorylation by MAPKAP kinase 2 (2005) (61)
Switching from life to death: the Miz-ing link between Myc and p53. (2002) (59)
Functions of human papillomavirus E6 and E7 oncoproteins. (1994) (59)
p73-alpha is capable of inducing scotin and ER stress (2004) (59)
MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity (2011) (57)
p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53 (2008) (57)
Assay for Ubiquitin Ligase Activity: High-Throughput Screen for Inhibitors of HDM2 (2004) (56)
Corrigendum: Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription (The EMBO Journal(1992)11(3045-3052)) (1992) (55)
p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. (1997) (55)
Contribution of membrane localization to the apoptotic activity of PUMA (2007) (53)
Analysis of human papillomavirus type 16 open reading frame E7 immortalizing function in rat embryo fibroblast cells. (1990) (52)
Fructose reprogrammes glutamine-dependent oxidative metabolism to support LPS-induced inflammation (2021) (52)
Metabolic effect of TAp63α: enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense (2014) (51)
Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. (1993) (49)
Cellular response to DNA damage from a potent carcinogen involves stabilization of p53 without induction of p21(waf1/cip1). (1997) (49)
Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies (1996) (47)
Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. (1995) (45)
Ubiquitination and proteasomal degradation of ATG12 regulates its proapoptotic activity (2014) (44)
HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. (1993) (44)
Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity (2017) (44)
Perturbation of the p53 response by human papillomavirus type 16 E7 (1997) (44)
Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family (2016) (42)
Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. (1996) (41)
A role for Numb in p53 stabilization (2008) (40)
Alternative fuel—another role for p53 in the regulation of metabolism (2010) (40)
Functions of TAp63 and p53 in restraining the development of metastatic cancer (2014) (39)
PHD1 regulates p53-mediated colorectal cancer chemoresistance (2015) (39)
Tumor Suppression by p53: Fall of the Triumvirate? (2012) (38)
Ubiquitin-specific Peptidase 42 (USP42) Functions to Deubiquitylate Histones and Regulate Transcriptional Activity* (2014) (38)
p 53 and its mutants in tumor cell migration and invasion (2011) (37)
Small molecules that bind the Mdm2 RING stabilize and activate p53. (2012) (37)
Both Immunization with Protein and Recombinant Vaccinia Virus Can Stimulate CTL Specific for the E7 Protein of Human Papilloma Virus 16 in H‐2d Mice (1995) (37)
Human papillomaviruses and cervical carcinoma. (1989) (36)
Functions of p53 in metabolism and invasion. (2009) (36)
ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis (2017) (36)
Human papillomavirus oncoproteins. (1990) (35)
E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia (2002) (35)
Biological activities of p53 mutants in Burkitt's lymphoma cells. (1993) (35)
Loss of Nuclear Factor-κB Is Tumor Promoting but Does Not Substitute for Loss of p53 (2004) (34)
iRFP is a sensitive marker for cell number and tumor growth in high-throughput systems (2014) (34)
Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression (1991) (33)
Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions. (2001) (32)
p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant (2018) (32)
Viruses and human cancer. (1994) (32)
p53- and p73-independent activation of TIGAR expression in vivo (2015) (29)
New HPV E6 binding proteins: dangerous liaisons? (1998) (29)
Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers (2012) (28)
Lack of p53-Mediated G1 Arrest in Response to an Environmental Carcinogen (1999) (27)
Mutational analysis of bovine papillomavirus E6 gene (1989) (26)
Cancer: Pinning a change on p53 (2002) (25)
Cancer: Guarding the guardian? (2004) (25)
p53-mediated induction of Noxa and p53AIP1 requires NFkappaB. (2010) (25)
Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. (1991) (24)
A novel deletion within the upstream regulatory region of episomal human papillomavirus type 16. (1989) (23)
Genetic and cellular mechanisms of oncogenesis. (2011) (22)
p53-mediated induction of Noxa and p53AIP1 requires NFκB (2010) (22)
Acetyltransferases and tumour suppression (2000) (22)
Localization of NADPH production: a wheel within a wheel. (2014) (22)
An indirect role for ASPP1 in limiting p53‐dependent p21 expression and cellular senescence (2012) (21)
DNA adduct levels associated with p53 induction and delay of MCF‐7 cells in S phase after exposure to benzo[g]chrysene dihydrodiol epoxide enantiomers (1998) (21)
Functional similarity between HPV16E7, SV40 large T and adenovirus E1a proteins. (1989) (20)
Mutant p53 in cell-cell interactions (2021) (19)
Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo (2017) (18)
The involvement of activated ras genes in determining the transformed phenotype (1985) (17)
Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6 (1998) (17)
Regulation of p 53 stability and function by the deubiquitinating enzyme USP 42 (2011) (17)
The p53 Tumor Suppressor Protein. (2000) (17)
Reversal of p53‐induced cell‐cycle arrest (1999) (17)
Functional analysis of human papillomavirus type 16 E7 by complementation with adenovirus E1A mutants. (1992) (16)
Activation of p53 DNA binding activity by point mutation (1998) (16)
Strategies for studying mouse and human immune responses to human papillomavirus type 16. (1994) (16)
The Secret Life of Histones (2003) (15)
Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain (2020) (15)
Interaction of HPV E6 with p53 and associated proteins. (1994) (15)
Scalable and robust SARS-CoV-2 testing in an academic center (2020) (15)
Partners in death: a role for p73 and NF-kB in promoting apoptosis (2009) (15)
Role of the Alternative INK 4 A Proteins in Human Keratinocyte Senescence : Evidence for the Specific Inactivation of p 16 INK 4 A upon Immortalization 1 (2000) (13)
Human papillomavirus and cancer : The viral transforming genes (1999) (12)
Patterns of in vitro behaviour characterizing cells of spontaneously metastasizing K2M rat sarcoma. (1987) (12)
A roadmap for the next decade in cancer research (2020) (12)
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2 (2013) (11)
p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl4 (2021) (11)
Taking up the reins of power: metabolic functions of p53 (2019) (11)
Oncogenes and tumour suppressors (1997) (10)
The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cells (2021) (9)
The Quid Pro Quo of the Tumor/Stromal Interaction. (2016) (8)
Erratum to: Metabolic regulation by p53 (2011) (8)
Mutational analysis reveals a dual role of Mdm2 acidic domain in the regulation of p53 stability (2012) (7)
Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice (2020) (6)
J . Biol . Chem . 23-10-2003 p 73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation (2003) (6)
PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma (2021) (6)
The ins and outs of p 53 (6)
iRFP Is a Real Time Marker for Transformation Based Assays in High Content Screening (2014) (6)
p53 and Mdm2: An auld alliance (2010) (5)
Suppression of acetate mutants in Coprinus (1983) (4)
Suppression of acetate mutants in Coprinus (1983) (4)
‘Stealth Properties’ Contribute to the Potent Action of Polycyclic Aromatic Hydrocarbon Carcinogens (2000) (4)
One carbon, many roads (2017) (4)
HPV E6: ensuring all's well at the end. (1996) (4)
HPV-16 and cervical intraepithelial neoplasia (1992) (3)
Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain (2020) (3)
Corrigendum: Modulating the therapeutic response of tumours to dietary serine and glycine starvation (2017) (3)
Human papillomaviruses and cancer of the cervix (1996) (3)
Regulation of Cell Growth and Death by p53 (2000) (2)
Location, location, location (2016) (2)
Mutational Analysis ofBovine Papillomavirus E6Gene (1989) (2)
Direct Estimation of Metabolic Flux by Heavy Isotope Labeling Simultaneous with Pathway Inhibition: Metabolic Flux Inhibition Assay. (2018) (2)
P53-Mediated Apoptosis (1996) (2)
Relation between lnfection with a Subtype of HPV16 and Cervical Neoplasia (1990) (1)
Oncogenes and growth control. EMBL-SALK Conference, Heidelberg, Germany, 18-22 April 1998. (1999) (1)
Karen Vousden: getting the big picture on p53. Interview by Caitlin Sedwick. (2012) (1)
The dietary sweetener sucralose is a negative modulator of T cell-mediated responses (2023) (1)
Regulation of the P53 tumour suppressor protein by MDM2 and MDMX (2008) (1)
Use of 13C315N1-Serine or 13C515N1-Methionine for Studying Methylation Dynamics in Cancer Cell Metabolism and Epigenetics. (2019) (1)
Oncoproteins Mdm2 and MdmX: Their roles in the regulation of the p53 tumour suppressor protein (2009) (1)
More Metabolism! (2021) (1)
1 Nix-mediated mitophagy promotes pancreatic cancer (2019) (1)
A non-invasive iRFP713 p53 reporter reveals dynamic p53 activity in response to irradiation and liver regeneration in vivo† (2022) (1)
Author Correction: Scalable and robust SARS-CoV-2 testing in an academic center (2020) (1)
The Regulation of TIGAR (2014) (1)
Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo (2017) (0)
TIGAR, TIGAR, burning bright (2014) (0)
Apoptotic cell death in disease—Current understanding of the NCCD 2023 (2023) (0)
Abstract PR14: CRISPR/Cas9-mediatedTrp53, Brca1, Brca2, Pten,andNf1knockout to generate improved murine models of ovarian high-grade serous carcinoma (2018) (0)
Corrigendum (2022) (0)
PO-403 The tumour suppressor P53 as a guardian of immune tolerance and suppression (2018) (0)
Identification and analysis of novel Mdm2/MdmX-interacting proteins involved in the regulation of the p53 tumour suppressor pathway (2010) (0)
Abstract A48: Metabolic adaptations to serine starvation (2016) (0)
Structure of native c-Cbl; c-Cbl-ZAP-70 peptide complex; phosphoTyr371-c-Cbl-UbcH5B-ZAP-70 complex; modified phosphoTyr371-c-Cbl-UbcH5B-ZAP-70 complex and phosphoTyr371-c-Cbl-UbcH5B complex (2012) (0)
Erratum to: Contribution of membrane localization to the apoptotic activity of PUMA (2012) (0)
5 A role for mutant p53 in promoting invasion (2010) (0)
The in vivo function of TIGAR, a p53 target gene that regulates glucose metabolism (2014) (0)
Phosphoglycerate Dehydrogenase Is Required for Germinal Center Formation and Is a Therapeutic Target in MYC-driven Lymphoma (2021) (0)
The in vivo function of TIGAR, a p53 target gene that regulates glucose metabolism (2014) (0)
151 Mutant P53 Gain of Function Via P63 (2012) (0)
Abstract SY42-03: One carbon metabolism and cancer (2015) (0)
Analysis of Mdm2 domains involved in p53 degradation (2009) (0)
Identification of differences in the primary structure of MDM2and MDMX ring domains that render MDMX inactive (2012) (0)
A celebration of the life of George Vande Woude (2021) (0)
Canagliflozin Impairs T-Cell Effector Function via Metabolic Suppression in Autoimmunity (2022) (0)
human PKM2 with L-serine and FBP bound. (2012) (0)
Abstract AP24: CRISPR/CAS9–MEDIATED TRP53, BRCA1, BRCA2 AND PTEN KNOCKOUT TO GENERATE IMPROVED MURINE MODELS OF OVARIAN HIGH GRADE SEROUS CARCINOMA (2017) (0)
Corrigendum: Serine is a natural ligand and allosteric activator of pyruvate kinase M2 (2013) (0)
The in vivo function of the p53 target gene TIGAR (2012) (0)
14: Balancing energetic and anabolic needs of cancer cells (2014) (0)
Analysis of MDM2 and MDMX domains involved in p53 ubiquitylation and degradation (2007) (0)
Finding clues in the p53 maze: an interview with Karen Vousden (2018) (0)
Structural analysis of MDM2-E2–ubiquitin interaction in p53 regulation (2017) (0)
Commentary Acetyltransferases and tumour suppression (2000) (0)
Structure of MDM2-MDMX-UbcH5B-ubiquitin complex (2017) (0)
Cancer-Speciﬁc Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses (2020) (0)
Chris Marshall (1949–2015) (2015) (0)
Structure of phosphoTyr371-c-Cbl-UbcH5B-ZAP-70 complex (2012) (0)
Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis. (2013) (0)
351 Identification and analysis of two novel Mdm2-interacting proteins involved in the regulation of cellular stress response pathways (2010) (0)
Abstract 6217: TP53 loss with whole genome doubling mediates heterogeneous intra-patient therapy response in EGFR-driven lung adenocarcinoma: A TRACERx study (2022) (0)
Identification and functional analysis of novel binding partners for oncoprotein Mdm2 (2009) (0)
SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay [version 1; peer review: awaiting peer review] (2021) (0)
79 Roles of p53 in the Control of Metabolic Pathways (2012) (0)
Abstract SY29-01: Functions of wild type and mutant p53 (2010) (0)
Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels (2018) (0)
Erratum to: Contribution of membrane localization to the apoptotic activity of PUMA (2012) (0)
Regulation of cellular stress response pathways by interactions between Mdm2 and transcription factor GTF2I (2009) (0)
A Conversation with Karen Vousden. (2016) (0)
p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant (2018) (0)
The Regulation of TIGAR (2014) (0)
Abstract A47: The regulation of TIGAR (2016) (0)
Identification and Characterization of a Minimal Apoptotic Domain from p53 (2001) (0)
upon Immortalization INK 4 A p 16 Senescence : Evidence for the Specific Inactivation of Proteins in Human Keratinocyte INK 4 A Role of the Alternative Updated (2000) (0)
Sir Frederick Gowland Hopkins Memorial Lecture Functions of p53 in metabolism and invasion (2009) (0)
Structure of phosphoTyr371-c-Cbl-UbcH5B complex (2012) (0)
Brexit negotiations: what is next for science? (2019) (0)
Identification and functional analysis of novel bindingpartners for oncoprotein Mdm2 (2009) (0)
Functional analysis of human papiliomavirus type 16 E 7 by complementation with adenovirus EIA mutants (2007) (0)
HPV-12 and cervical intraepithelial neoplasia (1992) (0)
Structure of modified phosphoTyr371-c-Cbl-UbcH5B-ZAP-70 complex (2012) (0)
Abstract IA18: Activities of wild-type and mutant p53 (2013) (0)
Mutations activating human c-Ha-rasl protooncogene (HRASI) induced by chemical carcinogens and depurination (carcinogen-DNA adducts/DNA transfectlon/oligonucleotlde probes) (0)
Corrigendum: Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice. (2021) (0)
Sir Frederick Gowland Hopkins Memorial Lecture Functions of p53 in metabolism and invasion (2009) (0)
' s response to reviews Title : Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre-and post-treatment prostatic biopsies from patients with advanced prostate cancer (2014) (0)

This paper list is powered by the following services:

Other Resources About Karen Vousden

en.wikipedia.org

What Schools Are Affiliated With Karen Vousden?

Karen Vousden is affiliated with the following schools: